https://www.selleckchem.com/products/gne-317.html
Patients who have recently received a hematopoietic cell transplant (HCT) are at higher risk of acute complications in the first weeks after discharge, especially during the COVID-19 pandemic. The aim of this study was to test the use of a telehealth platform for the follow-up of HCT patients during the first two weeks after discharge. In total, 21 patients who received autologous or allogeneic HCT for hematological malignancies were screened from April 30, 2020, to July 15, 2020. The telehealth platform assisted in the daily collection
Aimer
Commentaire
Partagez
